

AMERISOURCEBERGEN CORP  
Form 10-Q  
May 07, 2014  
[Table of Contents](#)

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE QUARTERLY PERIOD ENDED March 31, 2014**

**OR**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE TRANSITION PERIOD FROM \_\_\_\_\_ TO \_\_\_\_\_**

**Commission file number 1-16671**

**AMERISOURCEBERGEN CORPORATION**

(Exact name of registrant as specified in its charter)

Edgar Filing: AMERISOURCEBERGEN CORP - Form 10-Q

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**1300 Morris Drive, Chesterbrook, PA**  
(Address of principal executive offices)

**23-3079390**  
(I.R.S. Employer  
Identification No.)

**19087-5594**  
(Zip Code)

**(610) 727-7000**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of shares of common stock of AmerisourceBergen Corporation outstanding as of April 30, 2014 was 225,839,910.

Table of Contents

AMERISOURCEBERGEN CORPORATION

TABLE OF CONTENTS

	<b>Page No.</b>
<u>Part I. FINANCIAL INFORMATION</u>	
<u>Item 1.</u>	<u>Financial Statements (Unaudited)</u>
	<u>Consolidated Balance Sheets, March 31, 2014 and September 30, 2013</u> 2
	<u>Consolidated Statements of Operations for the three and six months ended March 31, 2014 and 2013</u> 3
	<u>Consolidated Statements of Comprehensive Income for the three and six months ended March 31, 2014 and 2013</u> 4
	<u>Consolidated Statements of Cash Flows for the six months ended March 31, 2014 and 2013</u> 5
	<u>Notes to Consolidated Financial Statements</u> 6
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> 15
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u> 27
<u>Item 4.</u>	<u>Controls and Procedures</u> 27
<u>Part II. OTHER INFORMATION</u>	
<u>Item 1.</u>	<u>Legal Proceedings</u> 28
<u>Item 1A.</u>	<u>Risk Factors</u> 28
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u> 28
<u>Item 3.</u>	<u>Defaults Upon Senior Securities</u> 28
<u>Item 4.</u>	<u>Mine Safety Disclosures</u> 28
<u>Item 5.</u>	<u>Other Information</u> 28
<u>Item 6.</u>	<u>Exhibits</u> 29
<u>SIGNATURES</u>	30

Table of Contents**PART I. FINANCIAL INFORMATION****ITEM I. Financial Statements (Unaudited)****AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS**

(in thousands, except share and per share data)	March 31, 2014 (Unaudited)	September 30, 2013
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 696,730	\$ 1,231,006
Accounts receivable, less allowances for returns and doubtful accounts: \$387,250 at March 31, 2014 and \$358,161 at September 30, 2013	6,506,412	6,051,920
Merchandise inventories	8,493,269	6,981,494
Prepaid expenses and other	63,616	129,231
Total current assets	15,760,027	14,393,651
Property and equipment, at cost:		
Land	37,538	37,538
Buildings and improvements	343,707	324,150
Machinery, equipment and other	1,208,114	1,109,731
Total property and equipment	1,589,359	1,471,419
Less accumulated depreciation	(738,512)	(667,858)
Property and equipment, net	850,847	803,561
Goodwill and other intangible assets	3,495,145	3,499,713
Other assets	255,228	221,713
<b>TOTAL ASSETS</b>	<b>\$ 20,361,247</b>	<b>\$ 18,918,638</b>
<b>LIABILITIES AND STOCKHOLDERS EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 14,909,626	\$ 13,335,792
Accrued expenses and other	587,185	532,564
Deferred income taxes	1,003,120	1,002,279
Total current liabilities	16,499,931	14,870,635
Long-term debt	1,396,948	1,396,606
Other liabilities	318,853	331,652
Stockholders' equity:		
Common stock, \$0.01 par value - authorized: 600,000,000 shares; issued and outstanding: 269,472,871 shares and 227,519,892 shares at March 31, 2014, respectively, and 267,789,992	2,695	2,678

Edgar Filing: AMERISOURCEBERGEN CORP - Form 10-Q

shares and 229,994,216 shares at September 30, 2013, respectively			
Additional paid-in capital		2,359,193	2,360,992
Retained earnings		1,621,479	1,508,414
Accumulated other comprehensive loss		(44,514)	(35,483)
Treasury stock, at cost: 41,952,979 shares at March 31, 2014 and 37,795,776 shares at September 30, 2013		(1,793,338)	(1,516,856)
Total stockholders' equity		2,145,515	2,319,745
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</b>	<b>\$</b>	<b>20,361,247</b>	<b>\$ 18,918,638</b>

See notes to consolidated financial statements.

Table of Contents

## AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES

## CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share data)	Three months ended March 31,		Six months ended March 31,	
	2014	2013	2014	2013
Revenue	\$ 28,455,903	\$ 20,523,668	\$ 57,632,265	\$ 41,583,479
Cost of goods sold	27,726,310	19,806,679	56,214,447	40,205,662
Gross profit	729,593	716,989	1,417,818	1,377,817
Operating expenses:				
Distribution, selling, and administrative	376,341	323,536	740,401	644,236
Depreciation	37,968	33,069	75,287	64,943
Amortization	6,526	6,799	13,157	13,609
Warrants	5,663	3,761	121,960	3,761
Employee severance, litigation and other	1,967	(299)	6,269	1,705
Operating income	301,128	350,123	460,744	649,563
Other (income) loss	(3,783)	749	(4,380)	726
Interest expense, net	19,474	18,510	38,306	37,035
Income from continuing operations before income taxes	285,437	330,864	426,818	611,802
Income taxes	105,360	126,721	197,810	233,038
Income from continuing operations	180,077	204,143	229,008	378,764
Loss from discontinued operations, net of income taxes		(158,509)	(7,546)	(164,519)
Net income	\$ 180,077	\$ 45,634	\$ 221,462	\$ 214,245
Earnings per share:				
Basic earnings per share:				
Continuing operations	\$ 0.78	\$ 0.89	\$ 1.00	\$ 1.64
Discontinued operations		(0.69)	(0.03)	(0.71)
Rounding			(0.01)	
Total	\$ 0.78	\$ 0.20	\$ 0.96	\$ 0.93
Diluted earnings per share:				
Continuing operations	\$ 0.76	\$ 0.87	\$ 0.97	\$ 1.61
Discontinued operations		(0.68)	(0.03)	(0.70)
Total	\$ 0.76	\$ 0.19	\$ 0.94	\$ 0.91
Weighted average common shares outstanding:				
Basic	229,409	230,422	229,852	231,409
Diluted	236,268	234,587	236,650	235,307
Cash dividends declared per share of common stock	\$ 0.235	\$ 0.21	\$ 0.47	\$ 0.42

See notes to consolidated financial statements.



Table of Contents

## AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES

## CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

(in thousands)	Three months ended March 31,		Six months ended March 31,	
	2014	2013	2014	2013
Net income	\$ 180,077	\$ 45,634	\$ 221,462	\$ 214,245
Other comprehensive (loss) income:				
Net change in foreign currency translation adjustments	(3,173)	(20,869)	(8,615)	(23,641)
Other	(265)	27	(416)	54
Total other comprehensive loss	(3,438)	(20,842)	(9,031)	(23,587)
Total comprehensive income	\$ 176,639	\$ 24,792	\$ 212,431	\$ 190,658

See notes to consolidated financial statements.



Table of Contents

## AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES

## CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)	Six months ended March 31,	
	2014	2013
<b>OPERATING ACTIVITIES</b>		
Net income	\$ 221,462	\$ 214,245
Loss from discontinued operations	7,546	164,519
Income from continuing operations	229,008	378,764
Adjustments to reconcile income from continuing operations to net cash provided by operating activities:		
Depreciation, including amounts charged to cost of goods sold	76,395	67,750
Amortization, including amounts charged to interest expense	15,556	15,897
Provision for doubtful accounts	13,095	4,383
(Benefit) provision for deferred income taxes	(11,143)	36,263
Warrants	121,960	3,761
Share-based compensation	22,018	18,504
Other	(6,309)	(5,157)
Changes in operating assets and liabilities, excluding the effects of acquisitions:		
Accounts receivable	(495,495)	(417,646)
Merchandise inventories	(1,486,055)	(174,507)
Prepaid expenses and other assets	27,083	988
Accounts payable, accrued expenses, and income taxes	1,612,833	766,508
Other liabilities	1,253	2,716
Net cash provided by operating activities - continuing operations	120,199	698,224
Net cash (used in) provided by operating activities - discontinued operations	(7,546)	45,431
<b>NET CASH PROVIDED BY OPERATING ACTIVITIES</b>	<b>112,653</b>	<b>743,655</b>
<b>INVESTING ACTIVITIES</b>		
Capital expenditures	(125,392)	(88,377)
Cost of acquired companies, net of cash acquired	(9,103)	
Other	6,360	81
Net cash used in investing activities - continuing operations	(128,135)	(88,296)
Net cash used in investing activities - discontinued operations		(9,643)
<b>NET CASH USED IN INVESTING ACTIVITIES</b>	<b>(128,135)</b>	<b>(97,939)</b>
<b>FINANCING ACTIVITIES</b>		
Borrowings under revolving and securitization credit facilities	16,133,500	2,325,000
Repayments under revolving and securitization credit facilities	(16,133,500)	(2,325,000)
Purchases of common stock	(251,961)	(284,691)
Exercises of stock options, including excess tax benefits of \$22,670 and \$15,941 in fiscal 2014 and 2013, respectively	59,675	65,850
Cash dividends on common stock	(108,397)	(98,203)
Purchases of capped call options	(211,397)	
Debt issuance costs and other	(6,714)	(6,086)
Net cash used in financing activities - continuing operations	(518,794)	(323,130)
Net cash used in financing activities - discontinued operations		(41,897)

Edgar Filing: AMERISOURCEBERGEN CORP - Form 10-Q

NET CASH USED IN FINANCING ACTIVITIES	(518,794)	(365,027)
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(534,276)	280,689
Cash and cash equivalents at beginning of period	1,231,006	1,066,608
CASH AND CASH EQUIVALENTS AT END OF PERIOD	\$ 696,730	\$ 1,347,297

See notes to consolidated financial statements.

Table of Contents

**AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**(UNAUDITED)**

**Note 1. Summary of Significant Accounting Policies**

*Basis of Presentation*

The accompanying financial statements present the consolidated financial position, results of operations and cash flows of AmerisourceBergen Corporation and its wholly owned subsidiaries (the Company) as of the dates and for the periods indicated. All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying unaudited consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (GAAP) for interim financial information, the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting only of normal recurring accruals, except as otherwise disclosed herein) considered necessary to present fairly the financial position as of March 31, 2014 and the results of operations and cash flows for the interim periods ended March 31, 2014 and 2013 have been included. Certain information and footnote disclosures normally included in financial statements presented in accordance with U.S. GAAP, but which are not required for interim reporting purposes, have been omitted. The accompanying unaudited consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2013.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts.

Certain reclassifications have been made to prior year amounts in order to conform to the current year presentation.

As of March 31, 2014, there were no recently issued accounting standards that will have a material impact on our financial position or results of operations upon their adoption.

**Note 2. Discontinued Operations**

## Edgar Filing: AMERISOURCEBERGEN CORP - Form 10-Q

In May 2013, the Company completed the divestiture of its packaging and clinical trials services business, AndersonBrecon ( AB ), and AmerisourceBergen Canada Corporation ( ABCC ). The Company has classified AB and ABCC s operating results, net of tax, as discontinued operations in the accompanying consolidated statements of operations for all periods presented. Prior to being classified within discontinued operations, AB was included in Other and ABCC was included in Pharmaceutical Distribution for segment reporting. AB and ABCC s revenue and loss before income taxes were as follows:

(in thousands)	Three months ended March 31,		Six months ended March 31,	
	2014	2013	2014	2013
Revenue	\$	\$ 441,277	\$	\$ 915,508
Loss before income taxes	\$	\$ (154,561)	\$ (7,546)	\$ (156,613)

The loss before income taxes in the six months ended March 31, 2014 includes the impact of a final purchase price working capital adjustment related to the divestiture of ABCC. The loss before income taxes in the three and six months ended March 31, 2013 includes a goodwill impairment charge of \$26.9 million and an estimated \$134.8 million loss on the sale of ABCC.

Table of Contents**AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS****(UNAUDITED)****Note 3. Income Taxes**

The Company files income tax returns in U.S. federal and state jurisdictions as well as various foreign jurisdictions. As of March 31, 2014, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company's financial statements, of \$58.7 million (\$41.5 million, net of federal benefit). If recognized, these tax benefits would reduce income tax expense and the effective tax rate. Included in this amount is \$9.4 million of interest and penalties, which the Company records in income tax expense. During the six months ended March 31, 2014, unrecognized tax benefits increased by \$3.3 million. During the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately \$10.5 million.

In March 2013, the Company issued Warrants (as defined in Note 6) in connection with various agreements and arrangements with Walgreen Co. (Walgreens) and Alliance Boots GmbH (Alliance Boots). As of the date of issuance, the Warrants were valued at \$242.4 million, which approximates the amount that will be deductible for income tax purposes. The fair value of the Warrants as of March 31, 2014 was \$700.0 million. The excess of the fair value as of March 31, 2014 over the initial value of \$242.4 million is not tax deductible. As a result, the Company's effective income tax rate for the six months ended March 31, 2014, which includes the impact of the Warrants, is higher than its historical rate.

**Note 4. Goodwill and Other Intangible Assets**

Following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the six months ended March 31, 2014 (in thousands):

	Pharmaceutical Distribution		Other		Total
Goodwill at September 30, 2013	\$	2,400,926	\$	544,044	\$ 2,944,970
Goodwill recognized in connection with acquisition				5,689	5,689
Foreign currency translation				(1,403)	(1,403)
Goodwill at March 31, 2014	\$	2,400,926	\$	548,330	\$ 2,949,256

Table of Contents

## AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Following is a summary of other intangible assets (in thousands):

	March 31, 2014			September 30, 2013		
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Indefinite-lived intangibles - trade names	\$ 343,735	\$	\$ 343,735	\$ 343,892	\$	\$ 343,892
Finite-lived intangibles:						
Customer relationships	268,465	(89,724)	178,741	265,810	(80,767)	185,043
Other	70,829	(47,416)	23,413	69,350	(43,542)	25,808
Total other intangible assets	\$ 683,029	\$ (137,140)	\$ 545,889	\$ 679,052	\$ (124,309)	\$ 554,743

Amortization expense for finite-lived intangible assets was \$13.2 million and \$13.6 million in the six months ended March 31, 2014 and 2013, respectively. Amortization expense for finite-lived intangible assets is estimated to be \$25.9 million in fiscal 2014, \$22.4 million in fiscal 2015, \$21.6 million in fiscal 2016, \$17.8 million in fiscal 2017, \$15.5 million in fiscal 2018, and \$112.1 million thereafter.

**Note 5. Debt**

Debt consisted of the following (in thousands):

	March 31, 2014	September 30, 2013
Multi-currency revolving credit facility due 2018	\$	\$
Receivables securitization facility due 2016		
Revolving credit note		
\$500,000, 5 7/8% senior notes due 2015	499,526	499,377
\$400,000, 4 7/8% senior notes due 2019	397,960	397,803
\$500,000, 3 1/2% senior notes due 2021	499,462	499,426
Total debt	\$ 1,396,948	\$ 1,396,606

The Company has a \$1.4 billion multi-currency senior unsecured revolving credit facility, which is scheduled to expire in July 2018 (the Multi-Currency Revolving Credit Facility), with a syndicate of lenders. Interest on borrowings under the Multi-Currency Revolving Credit

## Edgar Filing: AMERISOURCEBERGEN CORP - Form 10-Q

Facility accrues at specified rates based on the Company's debt rating and ranges from 68 basis points to 130 basis points over LIBOR / EURIBOR / Bankers Acceptance Stamping Fee, as applicable (90 basis points over LIBOR / EURIBOR / Bankers Acceptance Stamping Fee at March 31, 2014). Additionally, interest on borrowings denominated in Canadian dollars may accrue at the greater of the Canadian prime rate or the CDOR rate. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating, ranging from 7 basis points to 20 basis points, annually, of the total commitment (10 basis points at March 31, 2014). The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on,

Table of Contents

**AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**(UNAUDITED)**

among other things, indebtedness of excluded subsidiaries and asset sales, with which the Company was compliant as of March 31, 2014.

The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to \$1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest rates, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility.

The Company has a \$950 million receivables securitization facility ( Receivables Securitization Facility ), which is scheduled to expire in June 2016. The Company has available to it an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to \$250 million, subject to lender approval, for seasonal needs during the December and March quarters. During December 2013, the Company increased the availability of the Receivables Securitization Facility by \$250 million under the accordion feature. During March 2014, the Company elected to decrease the availability of the Receivables Securitization Facility back to \$950 million. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR plus a program fee of 75 basis points. The Company pays an unused fee of 40 basis points, annually, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of March 31, 2014.

The Company has an uncommitted, unsecured line of credit available to it pursuant to a revolving credit note ( Revolving Credit Note ). The Revolving Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed \$45 million. In April 2014, the Company entered into an amendment to the Revolving Credit Note to increase its maximum capacity to \$75 million. The Revolving Credit Note may be decreased or terminated by the bank or the Company at any time without prior notice.

**Note 6. Stockholders' Equity and Earnings per Share**

In November 2013, the Company's board of directors increased the quarterly cash dividend by 12% from \$0.21 per share to \$0.235 per share.

In November 2012, the Company's board of directors authorized a program allowing the Company to purchase up to \$750 million of its outstanding shares of common stock, subject to market conditions. During the six months ended March 31, 2014, the Company purchased 4.1 million shares of its common stock for a total of \$269.8 million. The Company had \$93.2 million of availability remaining under this share



## Edgar Filing: AMERISOURCEBERGEN CORP - Form 10-Q

repurchase program as of March 31, 2014. In August 2013, the Company's board of directors authorized a new program allowing the Company to purchase up to an additional \$750 million of its outstanding shares of common stock, subject to market conditions.

In March 2013, the Company, Walgreens, and Alliance Boots entered into various agreements and arrangements pursuant to which Walgreens and Alliance Boots together were granted the right to purchase a minority equity position in the Company, beginning with the right, but not the obligation, to purchase up to 19,859,795 shares of the Company's common stock (approximately 7% of the Company's common stock, on a fully diluted basis as of the date of issuance, assuming the exercise in full of the Warrants, as defined below) in open market transactions. In connection with these arrangements, Walgreens Pharmacy Strategies, LLC, a wholly owned subsidiary of Walgreens, was issued (a) a warrant to purchase up to 11,348,456 shares of the Company's common stock at an exercise price of \$51.50 per share exercisable during a six month period beginning in March 2016, and (b) a warrant to purchase up to 11,348,456 shares of the Company's common stock at an exercise price of \$52.50 per share exercisable during a six-month period beginning in March 2017 and Alliance Boots Luxembourg S.à.r.l., a wholly owned subsidiary of Alliance Boots, was issued (a) a warrant to purchase up to 11,348,456 shares of the Company's common stock at an exercise price of \$51.50 per share exercisable during a six-month period beginning in March 2016 and (b) a warrant to purchase up to 11,348,456 shares of the

Table of Contents**AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS****(UNAUDITED)**

Company's common stock at an exercise price of \$52.50 per share exercisable during a six-month period beginning in March 2017 (collectively, the Warrants).

The Company valued these Warrants as of March 18, 2013 (date of issuance) and revised the valuation each subsequent quarter. As of March 31, 2014, the Warrants with an exercise price of \$51.50 were valued at \$15.09 per share and the Warrants with an exercise price of \$52.50 were valued at \$15.75 per share. In total, the Warrants were valued at \$700.0 million as of March 31, 2014. Refer to "Critical Accounting Policies and Estimates - Warrants" in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2013 for a more detailed description of the accounting for the Warrants.

The Company has taken steps to mitigate the potentially dilutive effect that the exercise of the Warrants could have by hedging a portion of its future obligation to deliver common stock with a financial institution and repurchasing additional shares of its common stock for the Company's own account over time. In June 2013, the Company commenced its hedging strategy by entering into a contract with a financial institution pursuant to which it has executed a series of issuer capped call option transactions ("Capped Calls"). The Capped Calls give the Company the right to buy 60% of the shares of its common stock subject to the Warrants at specified prices at maturity, should the Warrants be exercised in 2016 and 2017 and assuming the Company's future share price does not exceed the cap price in the Capped Calls. If the Company's share price exceeds the cap price in the Capped Calls at the time the Warrants are exercised, the number of shares that will be delivered to the Company under the Capped Calls will be reduced, and accordingly, will cover less than 60% of the shares of common stock subject to the Warrants.

Through September 30, 2013, the Company purchased Capped Calls on 15.3 million shares of its common stock for a total premium of \$163.4 million. During the six months ended March 31, 2014, the Company completed this hedge transaction by purchasing Capped Calls on an additional 11.9 million shares of its common stock for a total premium of \$205.3 million. The Capped Calls permit the Company to acquire shares of its common stock at strike prices of \$51.50 and \$52.50 and have expiration dates ranging from February 2016 through October 2017. The Capped Calls permit net share settlement, which is limited by caps on the market price of the Company's common stock. The Company has accounted for the Capped Calls as equity contracts and therefore, the above premiums were recorded as a reduction to paid-in capital.

Basic earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the periods presented plus the dilutive effect of stock options, restricted stock, restricted stock units, and the Warrants.

(in thousands)	Three months ended March 31,		Six months ended March 31,	
	2014	2013	2014	2013
	229,409	230,422	229,852	231,409

Edgar Filing: AMERISOURCEBERGEN CORP - Form 10-Q

Weighted average common shares outstanding - basic				
Dilutive effect of stock options, restricted stock, and restricted stock units	4,863	4,165	4,985	3,898
Dilutive effect of Warrants	1,996		1,813	
Weighted average common shares outstanding - diluted	236,268	234,587	236,650	235,307

The potentially dilutive stock options that were antidilutive for the three and six months ended March 31, 2014 were 2.3 million and 1.8 million, respectively. There were no potentially dilutive stock options that were antidilutive for the three and six months ended March 31, 2013.

Table of Contents

**AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**(UNAUDITED)**

**Note 7. Legal Matters and Contingencies**

In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, and government investigations, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company establishes reserves based on its periodic assessment of estimates of probable losses. There can be no assurance that an adverse resolution of one or more matters during any subsequent reporting period will not have a material adverse effect on the Company's results of operations for that period or on the Company's financial condition.

***Qui Tam***

The qui tam provisions of the federal civil False Claims Act and various state and local civil False Claims Acts permit a private person, known as a relator or whistleblower, to file civil actions under these statutes on behalf of the federal, state and local governments. Such cases may involve allegations around the marketing, sale and/or purchase of pharmaceutical products. Qui tam complaints are initially filed by the relator under seal (or on a confidential basis) and the filing of the complaint imposes obligations on government authorities to investigate the allegations in the complaint and to determine whether or not to intervene in the action. Qui tam complaints remain sealed until the court in which the case was filed orders otherwise.

The Company has learned that there are filings in one or more federal district courts, including a qui tam complaint filed by one of its former employees, that are under seal and may involve allegations against the Company (and/or subsidiaries or businesses of the Company, including its group purchasing organization for oncologists and its oncology distribution business) relating to its distribution of certain pharmaceutical products to providers. The Company and AmerisourceBergen Specialty Group (ABSG) have also received subpoenas from the United States Attorney's Office for the Eastern District of New York (USAO) requesting production of documents and information relating to ABSG's oncology distribution center and former pharmacy in Dothan, Alabama, its group purchasing organization for oncologists, and intercompany transfers of certain oncology products, which the Company believes could be related to one or more of the qui tam actions that remain under seal. The Company is in the process of responding to the subpoenas and is cooperating fully with the USAO. The Company cannot predict the outcome of any pending action in which any AmerisourceBergen entity is or may become a defendant.

***Subpoenas from United States Attorney's Offices***

## Edgar Filing: AMERISOURCEBERGEN CORP - Form 10-Q

In fiscal 2012, the Company's subsidiary, AmerisourceBergen Drug Corporation ( ABDC ), received a subpoena from the United States Attorney's Office in New Jersey (the USAO) in connection with a grand jury proceeding requesting documents concerning ABDC's program for controlling and monitoring diversion of controlled substances into channels other than for legitimate medical, scientific, and industrial purposes. ABDC also received a subpoena from the Drug Enforcement Administration ( DEA ) in connection with the matter. In addition to requesting information on ABDC's diversion control program generally, the subpoenas also request documents concerning specific customers' purchases of controlled substances. ABDC has responded to the subpoenas and is cooperating fully with the USAO and the DEA. On August 30, 2013, ABDC received a second subpoena from the USAO requesting additional information related to the documents produced in response to the first subpoena, as well as information regarding additional specific customers' purchases of controlled substances. On December 31, 2013, ABDC received a third subpoena from the USAO requesting additional information related to electronically stored information. The Company cannot predict the outcome of this matter.

In fiscal 2013, the Company or ABDC has also received similar subpoenas from the United States Attorney's Office in the District of Kansas and the United States Attorney's Office in the Northern District of Ohio in connection with grand jury proceedings requesting documents in connection with ABDC's program for controlling and monitoring diversion of controlled substances into channels other than for legitimate medical, scientific and industrial purposes. As in the New Jersey matter described above, in addition to requesting information on ABDC's diversion control program generally, the subpoenas also request documents concerning specific

Table of Contents

**AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**(UNAUDITED)**

customers' purchases of controlled substances. The Company is in the process of responding to the subpoenas and cannot predict the outcome of these matters.

***West Virginia Complaint***

On June 26, 2012, the Attorney General of the State of West Virginia ( West Virginia ) filed a complaint (the Complaint ) in the Circuit Court of Boone County, West Virginia, against a number of pharmaceutical wholesale distributors, including the Company's subsidiary, ABDC, alleging, among other things, that the distributors failed to provide effective controls and procedures to guard against diversion of controlled substances for illegitimate purposes in West Virginia. The Complaint also alleges that the distributors acted negligently by distributing controlled substances to pharmacies that serve individuals who abuse prescription pain medication and were unjustly enriched by such conduct, violated consumer credit and protection laws, created a public nuisance, and violated state antitrust laws in connection with the distribution of controlled substances. West Virginia is seeking injunctive relief to enjoin alleged violations of state regulations requiring suspicious order monitoring and reporting and to require defendants to fund a medical monitoring treatment program. The Complaint also seeks a jury trial to determine any losses and damages sustained by West Virginia as a result of the defendants' alleged conduct. On July 26, 2012, one of the defendants, J.M. Smith Corporation d/b/a Smith Drug Company, filed a Notice of Removal from the Circuit Court of Boone County, West Virginia to the United States District Court for the Southern District of West Virginia, and ABDC and all other defendants filed Consents to Removal. On August 27, 2012, West Virginia filed a Motion to Remand, to which J.M. Smith Corporation d/b/a Smith Drug Company, joined by all other defendants, filed a reply. On March 27, 2013, the Court granted West Virginia's Motion to Remand and West Virginia notified the parties that they intended to file an amended complaint. In advance of filing an amended complaint, West Virginia served discovery requests and subsequently filed a motion to compel. After responding to West Virginia's motion to compel and oral argument, defendants were ordered to provide limited responses. On January 2, 2014, West Virginia filed an amended complaint, which removed the claims for unjust enrichment, medical monitoring and antitrust violations. On February 14, 2014, the defendants filed motions to dismiss the amended complaint. Those motions are currently pending before the court. The Company cannot predict the outcome of this matter.

**Note 8. Litigation Settlements**

***Antitrust Settlements***

Numerous class action lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. The Company has not been named a plaintiff in any of these class actions, but has been a member of the direct purchasers' class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the class actions have gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. During the three and six months ended March 31, 2014, the Company recognized gains of \$0.8 million and

\$21.9 million, respectively, relating to the above-mentioned class action lawsuits. During the three and six months ended March 31, 2013, the Company recognized gains of \$3.5 million and \$15.8 million, respectively, relating to the above-mentioned class action lawsuits. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company's consolidated statements of operations.

**Note 9. Fair Value of Financial Instruments**

The recorded amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable at March 31, 2014 and September 30, 2013 approximate fair value based upon the relatively short-term nature of these financial instruments. The recorded amount of long-term debt and the corresponding fair value as of March 31, 2014 were \$1,396.9 million and \$1,496.0 million, respectively. The recorded amount of long-term debt and the corresponding fair value as of September 30, 2013 were \$1,396.6

Table of Contents**AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS****(UNAUDITED)**

million and \$1,502.0 million, respectively. The fair values of debt were determined based on quoted market prices, otherwise known as Level 2 inputs.

**Note 10. Business Segment Information**

The Company is organized based upon the products and services it provides to its customers. The Company's operations are comprised of the Pharmaceutical Distribution reportable segment and Other. The Pharmaceutical Distribution reportable segment consists of the AmerisourceBergen Drug Corporation ( ABDC ) and AmerisourceBergen Specialty Group ( ABSG ) operating segments. Other consists of the AmerisourceBergen Consulting Services ( ABCS ) and World Courier Group, Inc. ( World Courier ) operating segments.

The following tables illustrate reportable segment information for the three and six months ended March 31, 2014 and 2013 (in thousands):

	Revenue					
	Three months ended March 31,			Six months ended March 31,		
	2014	2013	2014	2013	2014	2013
Pharmaceutical Distribution	\$ 27,932,495	\$ 20,054,159	\$ 56,555,086	\$ 40,653,207		
Other	572,503	514,942	1,176,635	1,019,992		
Intersegment eliminations	(49,095)	(45,433)	(99,456)	(89,720)		
Revenue	\$ 28,455,903	\$ 20,523,668	\$ 57,632,265	\$ 41,583,479		

Intersegment eliminations primarily represent the elimination of certain ABCS sales to the Pharmaceutical Distribution reportable segment.



Table of Contents**AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS****(UNAUDITED)**

	<b>Operating Income</b>			
	<b>Three months ended</b>		<b>Six months ended</b>	
	<b>March 31,</b>		<b>March 31,</b>	
	<b>2014</b>	<b>2013</b>	<b>2014</b>	<b>2013</b>
Pharmaceutical Distribution	\$ 372,929	\$ 321,077	\$ 659,711	\$ 587,754
Other	43,633	34,935	79,583	64,660
<b>Total segment operating income</b>	<b>416,562</b>	<b>356,012</b>	<b>739,294</b>	<b>652,414</b>
Gains on antitrust litigation settlements	849	3,456	21,872	15,764
LIFO (expense) credit	(102,828)	215	(160,410)	(952)
Acquisition related intangibles amortization	(5,825)	(6,098)	(11,783)	(12,197)
Warrants	(5,663)	(3,761)	(121,960)	(3,761)
Employee severance, litigation and other	(1,967)	299	(6,269)	(1,705)
<b>Operating income</b>	<b>301,128</b>	<b>350,123</b>	<b>460,744</b>	<b>649,563</b>
Other (income) loss	(3,783)	749	(4,380)	726
Interest expense, net	19,474	18,510	38,306	37,035
Income from continuing operations before income taxes	\$ 285,437	\$ 330,864	\$ 426,818	\$ 611,802

Segment operating income is evaluated by the chief operating decision maker for the Company before gains on antitrust litigation settlements; LIFO (expense) credit; acquisition related intangibles amortization; Warrants; employee severance, litigation and other; other (income) loss; and interest expense, net. All corporate office expenses are allocated to ABDC and ABSG within the Pharmaceutical Distribution reportable segment and to ABCS and World Courier within Other. Management believes that evaluating segment performance excluding the above items is meaningful because it provides insight with respect to operating results of the Company.

Table of Contents

**ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*Overview*

The following discussion should be read in conjunction with the Consolidated Financial Statements and notes thereto contained herein and in conjunction with the financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2013.

We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain. We are organized based upon the products and services we provide to our customers. Our operations are comprised of the Pharmaceutical Distribution reportable segment and Other.

*Pharmaceutical Distribution Segment*

The Pharmaceutical Distribution reportable segment is comprised of two operating segments, which include the operations of AmerisourceBergen Drug Corporation ( ABDC ) and AmerisourceBergen Specialty Group ( ABSG ). Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution segment's operations provide drug distribution and related services designed to reduce healthcare costs and improve patient outcomes.

ABDC distributes a comprehensive offering of brand-name and generic pharmaceuticals (including specialty pharmaceutical products), over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. ABDC also provides pharmacy management, staffing and other consulting services; scalable automated pharmacy dispensing equipment; medication and supply dispensing cabinets; and supply management software to a variety of retail and institutional healthcare providers. Additionally, ABDC delivers packaging solutions to institutional and retail healthcare providers.

ABSG, through a number of operating businesses, provides pharmaceutical distribution and other services primarily to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including dialysis clinics. ABSG also distributes plasma and other blood products, injectible pharmaceuticals and vaccines. Additionally, ABSG provides third party logistics and outcomes research, and other services for biotechnology and other pharmaceutical manufacturers.

Our use of the terms specialty and specialty pharmaceutical products refers to drugs used to treat complex diseases, such as cancer, diabetes and multiple sclerosis. Specialty pharmaceutical products are part of complex treatment regimens for serious conditions and diseases that generally require ongoing clinical monitoring. We believe the terms specialty and specialty pharmaceutical products are used consistently by industry participants and our competitors. However, we cannot be certain that other distributors of specialty products define these and other similar terms

in exactly the same manner as we do.

Both ABDC and ABSG distribute specialty drugs to their customers, with the principal difference between these two operating segments being that ABSG operates distribution facilities that focus primarily on complex disease treatment regimens. Therefore, a product distributed from one of ABSG's distribution facilities results in revenue reported under ABSG, and a product distributed from one of ABDC's distribution centers results in revenue reported under ABDC. Essentially all of ABSG sales consist of specialty pharmaceutical products. ABDC sales of specialty pharmaceutical products have historically been a relatively small component of its overall revenue.

*Other*

Other consists of the AmerisourceBergen Consulting Services ( ABCS ) operating segment and the World Courier Group, Inc. ( World Courier ) operating segment. The results of operations of our ABCS and World Courier operating segments are not significant enough to require separate reportable segment disclosure, and therefore, have been included in Other for the purpose of our reportable segment presentation.

Table of Contents

ABCS, through a number of operating businesses, provides commercialization support services including reimbursement support programs, outcomes research, contract field staffing, patient assistance and co-pay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry.

**Results of Operations****Revenue**

(dollars in thousands)	Three months ended March 31,			Six months ended March 31,			Change
	2014	2013	Change	2014	2013	Change	
Pharmaceutical Distribution	\$ 27,932,495	\$ 20,054,159	39.3%	\$ 56,555,086	\$ 40,653,207	39.1%	
Other	572,503	514,942	11.2%	1,176,635	1,019,992	15.4%	
Intersegment eliminations	(49,095)	(45,433)	8.1%	(99,456)	(89,720)	10.9%	
Revenue	\$ 28,455,903	\$ 20,523,668	38.6%	\$ 57,632,265	\$ 41,583,479	38.6%	

Revenue increased 38.6% from the prior year quarter and six month period. This increase was largely due to the revenue growth of Pharmaceutical Distribution and, to a lesser extent, the revenue growth of Other.

We currently expect our revenue in fiscal 2014 to increase between 30% and 34%. Our expected growth rate is driven primarily by our distribution contract with Walgreen Co. ( Walgreens ), which became effective on September 1, 2013. Fiscal 2014 will include eleven incremental months of brand drug distribution and the phase-in of generic drug distribution to Walgreens. Our future revenue growth will continue to be affected by various factors such as industry growth trends, including the introduction of new innovative brand therapies, the likely increase in the number of generic drugs that will be available over the next few years as a result of the expiration of certain drug patents held by brand-name pharmaceutical manufacturers, general economic conditions in the United States, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third party reimbursement rates to our customers, and changes in Federal government rules and regulations.

**Pharmaceutical Distribution Segment**

The Pharmaceutical Distribution segment grew its revenue by 39.3% and 39.1% from the prior year quarter and six month period, respectively. Intra-segment revenues between ABDC and ABSG have been eliminated in the presentation of total Pharmaceutical Distribution revenue. These revenues primarily consisted of ABSG sales directly to ABDC customer sites or ABSG sales to ABDC's facilities. Total intra-segment revenues were \$976.4 million and \$762.2 million in the quarters ended March 31, 2014 and 2013, respectively. Total intra-segment revenues were \$2.0 billion and \$1.6 billion in the six months ended March 31, 2014 and 2013, respectively.

## Edgar Filing: AMERISOURCEBERGEN CORP - Form 10-Q

ABDC's revenue of \$24.3 billion and \$49.2 billion in the quarter and six months ended March 31, 2014 increased 46.2% and 45.9%, respectively, from the prior year periods (before intrasegment eliminations). The increase in ABDC's revenue was primarily due to increased sales to Walgreens of \$6.6 billion and \$13.1 billion in the quarter and six months ended March 31, 2014, respectively, and increased sales to some of our other larger customers.

ABSG's revenue of \$4.6 billion and \$9.4 billion in the quarter and six months ended March 31, 2014 increased 9.8% and 9.0%, respectively, from the prior year periods (before intrasegment eliminations) primarily due to increased sales of certain specialty

Table of Contents

products and growth in its blood products, vaccine, and physician office distribution businesses. The physician office distribution business continues to benefit from sales of an ophthalmology drug.

The majority of ABSG's revenue is generated from the distribution of pharmaceuticals to physicians who specialize in a variety of disease states, especially oncology. Under federal sequestration legislation, Medicare physician reimbursement rates for Part B drugs were reduced on April 1, 2013. Community oncologists and other specialty physicians that administer drugs under Medicare Part B continue to be impacted by lower reimbursement rates for specialty pharmaceutical drugs. As a result, some physician practices continue to consider consolidation or selling their businesses to hospitals. While we service the needs of many hospitals, the continuing shift in this service channel has reduced community oncology revenue. (Refer to Item 1A. Risk Factors, in our Annual Report on Form 10-K for the fiscal year ended September 30, 2013 for a more detailed description of this business risk.) ABSG's business may continue to be adversely impacted in the future by changes in medical guidelines and the Medicare reimbursement rates for certain pharmaceuticals, especially oncology drugs administered by physicians. Since ABSG provides a number of services to or through physicians, any changes affecting this service channel could result in additional revenue reductions.

A number of our contracts with customers or group purchasing organizations (GPOs) are typically subject to expiration each year. We may lose a significant customer or GPO relationship if any existing contract with such customer or GPO expires without being extended, renewed, or replaced. During the six months ended March 31, 2014, no significant contracts expired. Over the next twelve months, the only significant contract scheduled to expire is our contract with the Department of Defense (DOD), which expires in March 2015. Our revenue, results of operations, and cash flows will be negatively impacted if the DOD contract is not renewed or the terms of the renewed contract are less favorable than the existing contract.

*Other*

Revenue in Other increased 11.2% and 15.4% from the prior year quarter and six month period, respectively, primarily due to our TheraCom distribution business within ABCS, which benefited from the launch of two new products in the middle of the prior fiscal year, and increased revenue from World Courier.

*Gross Profit*

(dollars in thousands)	Three months ended March 31,			Six months ended March 31,		
	2014	2013	Change	2014	2013	Change
Pharmaceutical Distribution	\$ 695,202	\$ 587,693	18.3%	\$ 1,289,408	\$ 1,115,826	15.6%
Other	136,370	125,625	8.6%	266,948	247,179	8.0%
Gains on antitrust litigation settlements	849	3,456		21,872	15,764	
LIFO (expense) credit	(102,828)	215		(160,410)	(952)	
Gross profit	\$ 729,593	\$ 716,989	1.8%	\$ 1,417,818	\$ 1,377,817	2.9%

Gross profit increased 1.8%, or \$12.6 million, and 2.9%, or \$40.0 million, from the prior year quarter and six month period, respectively.

Pharmaceutical Distribution gross profit increased 18.3%, or \$107.5 million, and 15.6%, or \$173.6 million, from the prior year quarter and six month period, respectively. These increases were primarily due to the higher sales volume to Walgreens, brand price appreciation, and the growth of our non-community oncology specialty distribution businesses. As a percentage of revenue, Pharmaceutical Distribution gross profit margin of 2.49% and 2.28% in the quarter and six months ended March 31, 2014 decreased 44 basis points and 46 basis points from the prior year quarter and six month period, respectively. These declines were primarily due

Table of Contents

to a significant increase in lower margin brand business with Walgreens and some of our other larger customers and competitive pressures on customer margins.

Gross profit in Other increased 8.6%, or \$10.7 million, and 8.0%, or \$19.8 million, from the prior year quarter and six month period, respectively. These increases were primarily due to higher revenue and improved gross margin in World Courier and higher revenue in TheraCom's distribution business. As a percentage of revenue, gross profit margin in Other of 23.82% in the quarter ended March 31, 2014 decreased from 24.40% in the prior year quarter. As a percentage of revenue, gross profit margin in Other of 22.69% in the six months ended March 31, 2014 decreased from 24.23% in the prior year six month period. These decreases were primarily due to increases in TheraCom's distribution revenue, which has a lower gross profit margin in comparison to other businesses within Other. These decreases were offset, in part, by increases in the gross profit margin of World Courier.

We recognized gains of \$0.8 million and \$3.5 million from antitrust litigation settlements with pharmaceutical manufacturers during the quarters ended March 31, 2014 and 2013, respectively. We recognized gains of \$21.9 million and \$15.8 million from antitrust litigation settlements with pharmaceutical manufacturers during the six months ended March 31, 2014 and 2013, respectively. The gains were recorded as reductions to cost of goods sold.

Our cost of goods sold for interim periods includes a last-in, first-out (LIFO) provision that is based on our estimated annual LIFO provision. We recorded a LIFO expense of \$102.8 million and a LIFO credit of \$0.2 million in the quarters ended March 31, 2014 and 2013, respectively. Our LIFO expense was \$160.4 million and \$1.0 million in the six months ended March 31, 2014 and 2013, respectively. The annual LIFO provision, which we estimate on a quarterly basis, is affected by expected changes in inventory quantities (such as the inventory build for the Walgreens business), product mix, and manufacturer pricing practices, which may be impacted by market and other external influences. Changes to any of the above factors can have a material impact to our annual LIFO provision.

*Operating Expenses*

(dollars in thousands)	Three months ended March 31,			Six months ended March 31,			Change
	2014	2013	Change	2014	2013	Change	
Distribution, selling and administrative	\$ 376,341	\$ 323,536	16.3%	\$ 740,401	\$ 644,236	14.9%	
Depreciation and amortization	44,494	39,868	11.6%	88,444	78,552	12.6%	
Warrants	5,663	3,761		121,960	3,761		
Employee severance, litigation and other	1,967	(299)		6,269	1,705		
Total operating expenses	\$ 428,465	\$ 366,866	16.8%	\$ 957,074	\$ 728,254	31.4%	

Distribution, selling and administrative expenses increased 16.3%, or \$52.8 million, from the prior year quarter, and increased 14.9%, or \$96.2 million from the prior year six-month period, primarily due to the on-boarding of our distribution agreement with Walgreens. More specifically, expenses relating to payroll, information technology and delivery were higher in the current year quarter and six month period.



Edgar Filing: AMERISOURCEBERGEN CORP - Form 10-Q

Depreciation expense increased from the prior year periods due to an increase in the amount of capital projects being depreciated. Amortization expense was comparable to the prior year periods.

Warrant expense was \$5.7 million and \$122.0 million in the quarter and six month period ended March 31, 2014, respectively, compared to \$3.8 million in both the prior year quarter and six month period. The Warrants were issued in March 2013 in connection with the agreements and arrangements that define our strategic relationship with Walgreens and Alliance Boots. Future

Table of Contents

Warrant expense could fluctuate significantly. (Refer to Critical Accounting Policies and Estimates Warrants in our Annual Report on Form 10-K for the fiscal year ended September 30, 2013 for a more detailed description of the accounting for the Warrants.)

Employee severance, litigation and other for the quarter ended March 31, 2014 included \$3.5 million of deal-related transaction costs offset in part by the net reversal of \$1.5 million of employee severance and other costs. Employee severance, litigation and other for the six months ended March 31, 2014 included \$5.7 million of deal-related transaction costs and \$0.6 million of employee severance and other costs. Employee severance, litigation and other for the quarter ended March 31, 2013 included the reversal of \$5.1 million of employee severance costs, offset by \$4.2 million of deal-related transaction costs, and \$0.6 million of facility closure and other costs. Employee severance, litigation and other for the six months ended March 31, 2013 included \$4.7 million of deal-related transaction costs and \$2.9 million of facility closure and other costs, offset by the reversal of \$5.9 million of employee severance costs.

As a percentage of revenue, operating expenses were 1.51% in the quarter ended March 31, 2014, a decrease of 28 basis points from the prior year quarter. For the six months ended March 31, 2014, operating expenses, as a percentage of revenue, were 1.66%, down 9 basis points from the prior year six month period. These decreases were primarily due to economies of scale as a result of the increased revenue provided by the Walgreens distribution agreement. The decrease in the six months ended March 31, 2014 was offset, in part, by the larger Warrant expense in the current year period.

**Operating Income**

(dollars in thousands)	Three months ended March 31,			Six months ended March 31,		
	2014	2013	Change	2014	2013	Change
Pharmaceutical Distribution	\$ 372,929	\$ 321,077	16.1%	\$ 659,711	\$ 587,754	12.2%
Other	43,633	34,935	24.9%	79,583	64,660	23.1%
Total segment operating income	416,562	356,012	17.0%	739,294	652,414	13.3%
Gains on antitrust litigation settlements	849	3,456		21,872	15,764	
LIFO (expense) credit	(102,828)	215		(160,410)	(952)	
Acquisition related intangibles amortization	(5,825)	(6,098)		(11,783)	(12,197)	
Warrants	(5,663)	(3,761)		(121,960)	(3,761)	
Employee severance, litigation and other	(1,967)	299		(6,269)	(1,705)	
Operating income	\$ 301,128	\$ 350,123	-14.0%	\$ 460,744	\$ 649,563	-29.1%

Segment operating income is evaluated before gains on antitrust litigation settlements; LIFO (expense) credit; acquisition related intangibles amortization; Warrants; and employee severance, litigation and other.

Pharmaceutical Distribution operating income increased 16.1%, or \$51.9 million, and 12.2%, or \$72.0 million, from the prior year quarter and six month period, respectively, due to the increases in gross profit, offset in part by the increases in operating expenses. As a percentage of revenue, Pharmaceutical Distribution operating income margin declined 26 basis points from the prior year quarter and declined 28 basis points from the prior year six month period due to a significant increase in lower margin brand business with Walgreens and some of our other larger customers.



Table of Contents

Operating income in Other increased 24.9%, or \$8.7 million, and 23.1%, or \$14.9 million, from the prior year quarter and six month period, respectively, primarily due to the increase in gross profit of World Courier.

Interest expense, interest income, and the respective weighted average interest rates in the quarters ended March 31, 2014 and 2013 were as follows (in thousands):

	2014		2013	
	Amount	Weighted Average Interest Rate	Amount	Weighted Average Interest Rate
Interest expense	\$ 19,577	3.85%	\$ 18,647	4.67%
Interest income	(103)	0.50%	(137)	0.29%
Interest expense, net	\$ 19,474		\$ 18,510	

Interest expense increased 5.2%, or \$1.0 million, from the prior year quarter due to an increase of \$338.2 million in variable rate average borrowings to fund seasonal working capital needs and the on-boarding of the Walgreens business.

Interest expense, interest income, and the respective weighted average interest rates in the six months ended March 31, 2014 and 2013 were as follows (in thousands):

	2014		2013	
	Amount	Weighted Average Interest Rate	Amount	Weighted Average Interest Rate
Interest expense	\$ 38,621	4.23%	\$ 37,384	4.68%
Interest income	(315)	0.48%	(349)	0.32%
Interest expense, net	\$ 38,306		\$ 37,035	

Interest expense increased 3.4%, or \$1.3 million, from the prior year six month period due to an increase of \$167.9 million in variable rate average borrowings.

Income taxes in the quarter ended March 31, 2014 reflect an effective income tax rate of 36.9%, compared to 38.3% in the prior year quarter. Income taxes in the six months ended March 31, 2014 reflect an effective tax rate of 46.3%, compared to 38.1% in the prior year period. The fluctuations in our effective tax rate were primarily the result of quarterly changes in the valuation of the Warrants for financial reporting purposes. Our future effective tax rate could fluctuate significantly depending upon the quarterly valuation of the Warrants for financial reporting purposes. Excluding the impact of Warrant expense, we expect that our effective tax rate in fiscal 2014 will be in the low 38% range.

Income from continuing operations of \$180.1 million in the quarter ended March 31, 2014 decreased 11.8% from the prior year quarter. Diluted earnings per share from continuing operations of \$0.76 in the quarter ended March 31, 2014 decreased 12.6% from \$0.87 per share in the prior year quarter. Income from continuing operations of \$229.0 million in the six months ended March 31, 2014 decreased 39.5% from the prior year period. Diluted earnings per share from continuing operations of \$0.97 in the six months ended March 31, 2014 decreased 39.8% from \$1.61 in the prior year period.

Loss from discontinued operations, net of income taxes, for all periods presented includes the operating results of AndersonBrecon ( AB ) and AmerisourceBergen Canada Corporation ( ABCC ), as well as a goodwill impairment charge and estimated loss on sale of ABCC in the quarter and six months ended March 31, 2013.

Table of Contents*Liquidity and Capital Resources*

The following table illustrates our debt structure at March 31, 2014, including availability under the multi-currency revolving credit facility, the receivables securitization facility and the revolving credit note (in thousands):

	Outstanding Balance	Additional Availability
<b>Fixed-Rate Debt:</b>		
\$500,000, 5 7/8% senior notes due 2015	\$ 499,526	\$
\$400,000, 4 7/8% senior notes due 2019	397,960	
\$500,000, 3 1/2% senior notes due 2021	499,462	
Total fixed-rate debt	1,396,948	
<b>Variable-Rate Debt:</b>		
Multi-currency revolving credit facility due 2018		1,400,000
Receivables securitization facility due 2016		950,000
Revolving credit note		45,000
Total variable-rate debt		2,395,000
Total debt	\$ 1,396,948	\$ 2,395,000

Along with our cash balances, our aggregate availability under our multi-currency revolving credit facility, our receivables securitization facility and the revolving credit note provides us sufficient sources of capital to fund our working capital requirements. We have increased seasonal needs related to our inventory build during the December and March quarters that, depending on our cash balance, can require the use of our credit facilities to fund short-term capital needs. Our cash balances in the six months ended March 31, 2014 and 2013 needed to be supplemented by intra-period credit facility borrowings to cover seasonal short-term working capital needs, which were higher in the six months ended March 31, 2014 due to the on-boarding of the Walgreens business. The greatest amount of variable-rate debt outstanding at any one time during the six months ended March 31, 2014 and 2013 was \$1.1 billion and \$595.0 million, respectively. The \$16.1 billion and \$2.3 billion of cumulative intra-period borrowings during the six months ended March 31, 2014 and 2013, respectively, were fully repaid by the end of each respective reporting period.

We have a \$1.4 billion multi-currency senior unsecured revolving credit facility, which is scheduled to expire in July 2018, (the Multi-Currency Revolving Credit Facility ) with a syndicate of lenders. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based on our debt rating and ranges from 68 basis points to 130 basis points over LIBOR / EURIBOR / Bankers Acceptance Stamping Fee, as applicable (90 basis points over LIBOR / EURIBOR / Bankers Acceptance Stamping Fee at March 31, 2014). Additionally, interest on borrowings denominated in Canadian dollars may accrue at the greater of the Canadian prime rate or the CDOR rate. We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on our debt rating, ranging from 7 basis points to 20 basis points, annually, of the total commitment (10 basis points at March 31, 2014). We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of excluded subsidiaries and asset sales, which we are compliant with as of March 31, 2014.

We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to \$1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest rates, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does



Table of Contents

not increase our borrowing capacity as it is fully backed by our Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under our commercial paper program at March 31, 2014.

We have a \$950 million receivables securitization facility ( Receivables Securitization Facility ), which is scheduled to expire in June 2016. We have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to \$250 million, subject to lender approval, for seasonal needs during the December and March quarters. During December 2013, we increased the availability of the Receivables Securitization Facility by \$250 million under the accordion feature. During March 2014, we elected to decrease the availability of the Receivables Securitization Facility back to \$950 million. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR plus a program fee of 75 basis points. We pay an unused fee of 40 basis points, annually, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, which we are compliant with as of March 31, 2014.

We have an uncommitted, unsecured line of credit available to us pursuant to a revolving credit note ( Revolving Credit Note ). The Revolving Credit Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed \$45 million. In April 2014, we entered into an amendment to the Revolving Credit Note to increase its maximum capacity to \$75 million. The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice.

We have \$500 million of 5 7/8% senior notes due September 15, 2015 (the 2015 Notes ), \$400 million of 4 7/8% senior notes due November 15, 2019 (the 2019 Notes ) and \$500 million of 3 1/2% senior notes due November 15, 2021 (the 2021 Notes ). Interest on the 2015 Notes, the 2019 Notes, and the 2021 Notes is payable semiannually in arrears. All of the senior notes rank pari passu to the Multi-Currency Revolving Credit Facility.

Our operating results have generated cash flow, which, together with availability under our debt agreements and credit terms from suppliers, has provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and repurchases of shares of our common stock.

Our primary ongoing cash requirements will be to finance working capital, fund the repayment of debt, fund the payment of interest on debt, fund repurchases of our common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities. In November 2012, our board of directors approved a program allowing us to purchase up to \$750 million shares of our common stock, subject to market conditions. During the fiscal year ended September 30, 2013, we purchased \$387.0 million of our common stock under the share repurchase program. During the six months ended March 31, 2014, we purchased \$269.8 million of our common stock under the share repurchase program, which included \$18.0 million of purchases that settled after March 31, 2014. As of March 31, 2014, we had \$93.2 million of availability remaining on the \$750 million share repurchase program. In August 2013, our board of directors approved a new program allowing us to purchase up to \$750 million additional shares of our common stock, subject to market conditions. We currently expect to purchase \$500 million of our common stock in fiscal 2014, subject to market conditions. Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements.

If Walgreens and/or Alliance Boots exercise their rights to purchase our common stock pursuant to the Warrants that we issued to them, the future issuances of shares of our common stock upon exercise of the Warrants will dilute the ownership interests of our then-existing stockholders and could adversely affect the market price of our common stock. We have taken steps to mitigate the potentially dilutive effect that exercise of the Warrants could have by hedging a portion of our future obligation to deliver common stock with a financial institution and repurchasing additional shares of our common stock for our own account over time. We will continue to explore additional opportunities to



## Edgar Filing: AMERISOURCEBERGEN CORP - Form 10-Q

mitigate the potentially dilutive effect of the Warrants. In June 2013, we commenced our hedging strategy by entering into a contract with a financial institution pursuant to which it has executed a series of issuer capped call transactions ( Capped Calls ). The Capped Calls give us the right to buy 60% of the shares of our common stock subject to the Warrants at specified prices at maturity, should the Warrants be exercised in 2016 and 2017 and assuming our future share price does not exceed the cap price in the Capped Calls. If our share price exceeds the cap price in the Capped Calls at the time the Warrants

Table of Contents

are exercised, the number of shares that will be delivered to us under the Capped Calls will be reduced, and accordingly, will cover less than 60% of the shares of common stock subject to the Warrants. If our future share price at the exercise dates is lower than our breakeven share price, then our use of capital for the purchase of the Capped Calls would be ineffective. To the extent the Capped Calls do not mitigate the dilutive effect of the Warrants, we intend to consider repurchasing additional shares of our common stock. The amount of dilution that we would be able to mitigate will depend on the relative costs and benefits of such a transaction, considering factors such as: our financial performance, the current and future share price of our common stock, our expected cash flows, competing priorities for capital, and overall market conditions.

We completed this hedge transaction in January 2014. During the six months ended March 31, 2014, we purchased Capped Calls on 11.9 million shares of our common stock for a total premium of \$211.4 million, which included a \$6.1 million payment for a hedge premium accrued at September 30, 2013. In total, under this hedge transaction, we purchased Capped Calls on 27.2 million shares of our common stock for a total premium of \$368.7 million.

Deterioration in general economic conditions could adversely affect the amount of prescriptions that are filled and the amount of pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers. In addition, volatility in financial markets may also negatively impact our customers' ability to obtain credit to finance their businesses on acceptable terms. Reduced purchases by our customers or changes in the ability of our customers to remit payments to us could adversely affect our revenue growth, our profitability, and our cash flow from operations.

We have market risk exposure to interest rate fluctuations relating to our debt. We manage interest rate risk by using a combination of fixed-rate and variable-rate debt. At March 31, 2014, we had no variable-rate debt outstanding. The amount of variable-rate debt fluctuates during the year based on our working capital requirements. We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates. However, there are no assurances that such instruments will be available in the combinations we want and on terms acceptable to us. There were no such financial instruments in effect at March 31, 2014.

We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents. We had \$696.7 million in cash and cash equivalents at March 31, 2014. The unfavorable impact of a hypothetical decrease in interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt. For every \$100 million of cash invested that is in excess of variable-rate debt, a 10 basis point decrease in interest rates would increase our annual net interest expense by \$0.1 million.

We are exposed to foreign currency and exchange rate risk from our non-U.S. operations. Our largest exposure to foreign exchange rates exists primarily with the Canadian Dollar, the Euro, and the U.K. Pound Sterling. We may utilize foreign currency denominated forward contracts to hedge against changes in foreign exchange rates. We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes. As of March 31, 2014, we had one foreign currency denominated contract outstanding that hedges the foreign currency exchange risk of the C\$50.0 million note that we received in conjunction with the sale of ABCC in May 2013.

Changes in the price and volatility of our common stock may have a significant impact on the fair value of the Warrants issued to Walgreens and Alliance Boots (see Note 6). As of March 31, 2014, a one dollar change in our common stock, holding other assumptions constant, would increase or decrease the fair value of the Warrants by approximately \$35 million and a one percent change in volatility, holding other assumptions constant, would increase or decrease the fair value of the Warrants by approximately \$14 million.



Table of Contents

Following is a summary of our contractual obligations for future principal and interest payments on our debt, minimum rental payments on our noncancelable operating leases and minimum payments on our other commitments at March 31, 2014 (in thousands):

	Total	Payments Due by Period			
		Within 1 Year	1-3 Years	4-5 Years	After 5 Years
Debt, including interest payments	\$ 1,701,063	\$ 66,375	\$ 588,688	\$ 74,000	\$ 972,000
Operating leases	291,938	56,692	94,170	67,069	74,007
Other commitments	101,865	65,848	36,017		
Total	\$ 2,094,866	\$ 188,915	\$ 718,875	\$ 141,069	\$ 1,046,007

We have commitments to purchase product from influenza vaccine manufacturers through the 2015/2016 flu season. We are required to purchase doses at prices that we believe will represent market prices. We currently estimate our remaining purchase commitment under these agreements will be approximately \$50.3 million as of March 31, 2014, of which \$25.2 million represents our commitment over the next twelve months, and are included in Other commitments in the above table.

We have outsourced to IBM Global Services ( IBM ) a significant portion of our corporate and ABDC information technology activities. The remaining commitment under our 10-year arrangement, as amended, which expires in June 2015, is approximately \$38.3 million as of March 31, 2014, of which \$30.7 million represents our commitment over the next twelve months, and is included in Other commitments in the above table.

Our liability for uncertain tax positions was \$58.7 million (including interest and penalties) as of March 31, 2014. This liability represents an estimate of tax positions that we have taken in our tax returns which may ultimately not be sustained upon examination by taxing authorities. Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.

During the six months ended March 31, 2014, our operating activities provided \$112.7 million of cash in comparison to cash provided of \$743.7 million in the prior year period. Cash provided by operations during the six months ended March 31, 2014 was principally the result of income from continuing operations of \$229.0 million, an increase in accounts payable, accrued expenses, and income taxes of \$1.6 billion, and non-cash items of \$231.6 million, offset, in part, by an increase in merchandise inventories of \$1.5 billion and an increase in accounts receivable of \$495.5 million. Accounts receivable increased from September 30, 2013, reflecting the increased volume associated with our new Walgreens business. We also increased our merchandise inventories at March 31, 2014 to support the increase in volume due to the new Walgreens business and consistent with prior years, due to seasonal needs. The increase in accounts payable, accrued expenses and income taxes was primarily driven by the increase in merchandise inventories.

Table of Contents

We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance. The increase in days sales outstanding from the prior year quarter and six month period reflects the increased sales volume and payment terms under the Walgreens distribution contract.

	Quarter ended March 31,		Six months ended March 31,	
	2014	2013	2014	2013
Days sales outstanding	20.5	18.7	20.3	18.6
Days inventory on hand	29.3	27.2	28.1	26.4
Days payable outstanding	45.5	45.4	43.9	44.0

Our cash flow from operating activities can vary significantly from period to period based on fluctuations in our period end working capital. We expect cash from operating activities in fiscal 2014 to be between \$800 million and \$1.0 billion. Operating cash uses during the six months ended March 31, 2014 included \$34.2 million of interest payments and \$72.3 million of income tax payments, net of refunds.

During the six months ended March 31, 2013, our operating activities provided \$743.7 million of cash. Cash provided by operations during the six months ended March 31, 2013 was principally the result of income from continuing operations of \$378.8 million, an increase in accounts payable, accrued expenses, and income taxes of \$766.5 million, and non-cash items of \$141.4 million, offset, in part, by an increase in accounts receivable of \$417.6 million and an increase in merchandise inventories of \$174.5 million. Accounts receivable increased from September 30, 2012, reflecting the increased volume associated with our largest pharmacy benefit manager ( PBM ) customer contract, which became effective on October 1, 2012, and was offset in part by strong customer cash collections. Additionally, while the payment terms in the PBM customer contract are favorable, they are longer than the payment terms in the previous contract. As a result, there was a negative impact to our working capital in the six months ended March 31, 2013. We also increased our merchandise inventories at March 31, 2013 to support the increase in volume due to the PBM customer contract. The increase in accounts payable, accrued expenses and income taxes was primarily driven by the increase in merchandise inventories and the timing of payments to our suppliers.

Capital expenditures for the six months ended March 31, 2014 and 2013 were \$125.4 million and \$88.4 million, respectively. Significant capital expenditures in the six months ended March 31, 2014 included infrastructure and technology-related costs to on-board the incremental Walgreens distribution volume, costs associated with building our new national distribution center, and other technology initiatives, including costs related to the further development of our enterprise resource planning ( ERP ) system. We expect to spend approximately \$300 million for capital expenditures during fiscal 2014. Significant capital expenditures in the six months ended March 31, 2013 included the purchase of one of our leased distribution facilities, technology initiatives including costs related to the further development of our ERP system, and expansion costs related to one of ABDC s facilities.

During the six months ended March 31, 2014 and 2013, we paid \$252.0 million and \$284.7 million, respectively, for purchases of our common stock. During the six months ended March 31, 2014, we paid \$211.4 million to purchase Capped Calls to hedge the potential dilution associated with the Warrants upon their exercise.

In November 2012, our board of directors increased the quarterly cash dividend by 62% from \$0.13 per share to \$0.21 per share. In November 2013, our board of directors increased the quarterly cash dividend by 12% from \$0.21 per share to \$0.235 per share. We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remains within the discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.



Table of Contents

*Cautionary Note Regarding Forward-Looking Statements*

Certain of the statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as expect, likely, outlook, forecast, would, could, should, can, will, project, in, sustain, synergy, on track, believe, seek, estimate, anticipate, may, possible, assume, variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and change in circumstances. These statements are not guarantees of future performance and are based on assumptions that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: changes in pharmaceutical market growth rates; the loss of one or more key customer or supplier relationships; the retention of key customer or supplier relationships under less favorable economics; changes in customer mix; customer delinquencies, defaults or insolvencies; supplier defaults or insolvencies; changes in branded and/or generic pharmaceutical manufacturers' pricing and distribution policies or practices; adverse resolution of any contract or other dispute with customers or suppliers; federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances, federal and state prosecution of alleged violations of related laws and regulations, and any related litigation, including shareholder derivative lawsuits or other disputes relating to our distribution of controlled substances; qui tam litigation for alleged violations of fraud and abuse laws and regulations and/or any other laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services and any related litigation, including shareholder derivative lawsuits; changes in federal and state legislation or regulatory action affecting pharmaceutical product pricing or reimbursement policies, including under Medicaid and Medicare, and the effect of such changes on our customers; changes in regulatory or clinical medical guidelines and/or labeling for the pharmaceutical products we distribute; price inflation in branded and generic pharmaceuticals and price deflation in generics; greater or less than anticipated benefit from launches of the generic versions of previously patented pharmaceutical products; significant breakdown or interruption of our information technology systems; our inability to realize the anticipated benefits of the implementation of an enterprise resource planning (ERP) system; interest rate and foreign currency exchange rate fluctuations; risks associated with international business operations, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic sanctions and import laws and regulations; economic, business, competitive and/or regulatory developments in countries where we do business and/or operate outside of the United States; risks associated with the strategic, long-term relationship among Walgreen Co., Alliance Boots GmbH, and AmerisourceBergen, the occurrence of any event, change or other circumstance that could give rise to the termination, cross-termination or modification of any of the transaction documents among the parties (including, among others, the distribution agreement or the generics agreement), an impact on our earnings per share resulting from the issuance of the Warrants, an inability to realize anticipated benefits (including benefits resulting from participation in the Walgreens Boots Alliance Development GmbH joint venture), the disruption of AmerisourceBergen's cash flow and ability to return value to its stockholders in accordance with its past practices, disruption of or changes in vendor, payer and customer relationships and terms, and the reduction of AmerisourceBergen's operational, strategic or financial flexibility; the acquisition of businesses that do not perform as we expect or that are difficult for us to integrate or control; our inability to successfully complete any other transaction that we may wish to pursue from time to time; changes in tax laws or legislative initiatives that could adversely affect our tax positions and/or our tax liabilities or adverse resolution of challenges to our tax positions; increased costs of maintaining, or reductions in our ability to maintain, adequate liquidity and financing sources; volatility and deterioration of the capital and credit markets; natural disasters or other unexpected events that affect our operations; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting our business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this report, (ii) in Item 1A (Risk Factors) in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2013 and elsewhere in that report and (iii) in other reports filed by the Company pursuant to the Securities Exchange Act.

Table of Contents

**ITEM 3. Quantitative and Qualitative Disclosures About Market Risk**

The Company's most significant market risks are the effects of changing interest rates, foreign currency risk, and changes in the price and volatility of the Company's common stock. See the discussion under "Liquidity and Capital Resources" in Item 2 on page 23.

**ITEM 4. Controls and Procedures**

*Evaluation of Disclosure Controls and Procedures*

The Company maintains disclosure controls and procedures that are intended to ensure that information required to be disclosed in the Company's reports submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also are intended to ensure that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

The Company's Chief Executive Officer and Chief Financial Officer, with the participation of other members of the Company's management, have evaluated the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) and have concluded that the Company's disclosure controls and procedures were effective for their intended purposes as of the end of the period covered by this report.

*Changes in Internal Control over Financial Reporting*

There were no changes during the fiscal quarter ended March 31, 2014 in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, those controls.



Table of Contents**PART II. OTHER INFORMATION****ITEM 1. Legal Proceedings**

See Note 7 (Legal Matters and Contingencies) of the Notes to the Consolidated Financial Statements set forth under Item 1 of Part I of this report for the Company's current description of legal proceedings.

**ITEM 1A. Risk Factors**

None.

**ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds****(c) Issuer Purchases of Equity Securities**

The following table sets forth the number of shares purchased, the average price paid per share, the total number of shares purchased as part of publicly announced programs, and the approximate dollar value of shares that may yet be purchased under the programs during each month in the quarter ended March 31, 2014.

Period	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs
January 1 to January 31	1,396,563	\$ 67.42	1,396,563	\$ 999,218,151
February 1 to February 28	626,292	\$ 65.43	529,849	\$ 964,796,731
March 1 to March 31	1,851,371	\$ 65.69	1,851,185	\$ 843,187,956
Total	3,874,226		3,777,597	

**ITEM 3. Defaults Upon Senior Securities**

None.

**ITEM 4. Mine Safety Disclosures**

None.

**ITEM 5. Other Information**

None.

Table of Contents

**ITEM 6. Exhibits**

**(a) Exhibits:**

- 3.1 Amended and Restated Certificate of Incorporation of the Registrant, as of March 4, 2010, as amended by the Certificate of Amendment dated as of February 17, 2011 and the Certificate of Amendment dated as of March 6, 2014.
- 3.2 Amendment and Restated Bylaws of the Registrant, dated as of March 6, 2014 (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K filed on March 10, 2014).
- 10.1 AmerisourceBergen Corporation Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on March 10, 2014).
- 10.2 Form of Restricted Stock Award Agreement to Non-Employee Director under the AmerisourceBergen Corporation Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed on March 10, 2014).
- 10.3 Form of Restricted Stock Unit Agreement to Non-Employee Director under the AmerisourceBergen Corporation Omnibus Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant's Current Report on Form 8-K filed on March 10, 2014).
- 10.4 Form of Nonqualified Stock Option Award Agreement to Employee under the AmerisourceBergen Corporation Omnibus Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant's Current Report on Form 8-K filed on March 10, 2014).
- 10.5 Form of Restricted Stock Unit Agreement to Employee under the AmerisourceBergen Corporation Omnibus Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant's Current Report on Form 8-K filed on March 10, 2014).
- 10.6 Form of Performance Share Award Agreement to Employee under the AmerisourceBergen Corporation Omnibus Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant's Current Report on Form 8-K filed on March 10, 2014).
- 31.1 Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
- 31.2 Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
- 32 Section 1350 Certifications of Chief Executive Officer and Chief Financial Officer.
- 101 Financial statements from the Quarterly Report on Form 10-Q of AmerisourceBergen Corporation for the quarter ended March 31, 2014, formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Income, (iv) the Consolidated Statements of Cash Flows, and (v) the Notes to Consolidated Statements.

Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**AMERISOURCEBERGEN CORPORATION**

May 7, 2014

/s/ Steven H. Collis  
Steven H. Collis  
President and Chief Executive Officer

May 7, 2014

/s/ Tim G. Guttman  
Tim G. Guttman  
Senior Vice President  
and Chief Financial Officer

Table of Contents

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
3.1	Amended and Restated Certificate of Incorporation of the Registrant, as of March 4, 2010, as amended by the Certificate of Amendment dated as of February 17, 2011 and the Certificate of Amendment dated as of March 6, 2014.
3.2	Amendment and Restated Bylaws of the Registrant, dated as of March 6, 2014 (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K filed on March 10, 2014).
10.1	AmerisourceBergen Corporation Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on March 10, 2014).
10.2	Form of Restricted Stock Award Agreement to Non-Employee Director under the AmerisourceBergen Corporation Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed on March 10, 2014).
10.3	Form of Restricted Stock Unit Agreement to Non-Employee Director under the AmerisourceBergen Corporation Omnibus Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant's Current Report on Form 8-K filed on March 10, 2014).
10.4	Form of Nonqualified Stock Option Award Agreement to Employee under the AmerisourceBergen Corporation Omnibus Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant's Current Report on Form 8-K filed on March 10, 2014).
10.5	Form of Restricted Stock Unit Agreement to Employee under the AmerisourceBergen Corporation Omnibus Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant's Current Report on Form 8-K filed on March 10, 2014).
10.6	Form of Performance Share Award Agreement to Employee under the AmerisourceBergen Corporation Omnibus Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant's Current Report on Form 8-K filed on March 10, 2014).
31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
32	Section 1350 Certifications of Chief Executive Officer and Chief Financial Officer.
101	Financial statements from the Quarterly Report on Form 10-Q of AmerisourceBergen Corporation for the quarter ended March 31, 2014, formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Income, (iv) the Consolidated Statements of Cash Flows, and (v) the Notes to Consolidated Statements.